Debio 4126, a new 12-week octreotide formulation, provides maintenance of disease control in patients with acromegaly switching from long-acting somatostatin analogues (SSAs) – preliminary results

Simona Ispas-Jouron¹, Annick Menetrey¹, Dalit Rechavi-Robinson¹, Daniel Biasse¹, Moritz Marquardt¹, Bruno Gavillet¹, Claire Laprun¹, Anne Bellon¹, Pedro Caetano¹, Przemysław Witek², Mikkel Andreassen³, Philippe Chanson⁴, Thierry Brue⁵

¹ Debiopharm International SA, Lausanne, Switzerland;
² Medical University of Warsaw, Department of Internal Medicine Endocrinology and Diabetes, Warsaw, Poland;
³ Rigshospitalet, Department of Endocrinology, Copenhagen, Denmark;
⁴ Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction et Centre de Référence des Maladies Rares de l’Hypophyse (HYPO), Le Kremlin-Bicêtre, France;
⁵ Hôpital de la Conception, Service d’endocrinologie, diabète, maladies métaboliques, Marseille, France

Introduction

Debiopharm International SA is developing Debio 4126, a 12‑week octreotide formulation, for the treatment of patients with acromegaly. Preliminary results from acromegaly patients in an ongoing trial, Debio 4126-102, are presented here for the first time.